A hybrid approach may increase the risk of certain adverse events, according to a new meta-analysis focused on long-term outcomes. 

Abbott's HeartMate 3 LVAD is the only FDA-approved device of its kind currently available in the United States. Should reports of adverse events worry cardiologists? Or are they to be expected when treating such a vulnerable patient population?

This small, low-cost practice change is a promising way to increase cancer screening participation, researchers detailed recently. 

While GLP-1 drugs were originally developed to treat diabetes, researchers keep finding additional ways these medications can potentially benefit patients.

Buzzworthy developments of the past few days.

Americans aren’t OK with generative healthcare AI that was developed without physicians and is sold by vendors without track records. 

Big as it is, the hospital piece represented just a 2.2% bump over 2021—a modest increase compared with 2021’s spike of 4.5% over 2020.

AI-based prediction models have shown significant promise, but many are still flawed in a way that limits their value.